Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 918

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 5
Chunk 918
---
Market
Information

Our
common stock commenced trading on the Nasdaq Capital Market, under the symbol “SHPH” on August 31, 2022. Prior to that time,
our common stock was not traded on any exchange or quoted on any over the counter market.

Holders

As
of February 7, 2025, we had 61 holders of record of our common stock and 4,076,567 shares of common stock issued and outstanding.

Dividends

We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings
(if any) will be retained for the development of our business and no dividends will be declared or paid on our common stock. Any future
dividends on our common stock will be subject to the discretion of our board of directors and will depend upon, among other things, our
earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent facts.

Preferred
dividends

As
of the date of this Annual Report, we have not issued any preferred stock nor paid any preferred dividends.

Recent
Sales of Unregistered Securities

During
the past three years, we effected the following transactions in reliance upon exemptions from registration under the Securities Act:

On
February 8, 2022 and March 11, 2022, the Company sold to certain accredited investors $365,000 and $225,000, respectively, in 6% convertible
notes (the “Notes”), which bore 6% interest, were repayable on December 31, 2024, and converted automatically into shares
of common stock or, in the event that units were sold in the offering, units, at a conversion price of $32.00 per unit upon closing of
our IPO. Such notes were sold to accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities
Act. Boustead Securities LLC acted as placement agent and received compensation of (i) $36,500 in cash and warrants to purchase 10% of
the total number of shares issuable upon conversion of the Convertible Notes, exercisable at the conversion price of the Convertible
Notes for the February offering and (ii) $22,750 in cash and warrants to purchase 10% of the total number of shares issuable upon conversion
of the Convertible Notes, exercisable at the conversion price of the Convertible Notes for the